Patrys Ltd: Update on GMP manufacturing run of PAT-DX1
Patrys Ltd: Appendix 4C - Quarterly - 31 March 2024
Patrys Ltd: Positive preclinical data for deoxymabs in vasculitis
Patrys Ltd: Change of Director's Interest Notice
Patrys Ltd: Presentation to highlight broader potential of Deoxymabs
Patrys Ltd: Appendix 4C - Quarterly - 31 December 2023
Patrys Ltd: Change of Director's Interest Notice
Patrys Ltd: GMP Production of PAT-DX1 Next Quarter
Patrys Ltd: Change of Director's Interest Notices x2
Patrys Ltd: Notification of Expiry of PABOA Listed Options
Patrys Ltd: Patrys Receives R&D Tax Incentive Refund
Patrys Ltd: Appendix 4C - Quarterly - 30 September 2023
Patrys Ltd: Data to be presented at leading brain cancer conference
Patrys Ltd: Final Director's Interest Notice
Patrys Ltd: Appendix 4G and Corporate Governance Statement
Patrys Ltd: Change of Director's Interest Notice
Patrys Ltd: Appendix 4C - Quarterly - 30 June 2023
Patrys Ltd: PAT-DX1 GLP toxicology reports received
Patrys Ltd: Appendix 4C - Quarterly - 31 March 2023
Patrys Ltd: Two new deoxymab patents granted in the USA
No Data